Navigation Links
Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
Date:7/30/2009

irman.

Tajib A. Mirzabekov, Ph.D., President and CEO of MSM commented: "This is a very exciting transaction for MSM. We are working with a great partner, on a very exciting and valuable target and we have the chance to launch what may be the first novel biologic in Russia through our Russian subsidiary, Meprotek. It provides a substantial validation for our technology and our team to work with a company of Debiopharm's caliber. There is a great need in targeting of GPCRs with functionally active, high quality and potent human monoclonal antibodies."

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

About MSM Protein Technologies

MSM is a closely held drug discovery company based in Boston, MA. MSM is the leader in the discovery of antibodies targeting multispanning membrane proteins. The company applies its proprietary SIMPL (TM) platform and magnetic proteoliposome particles (MPLs) to display multispanners such as GPCRs in highly concentrated and purified form while retaining their native conformation and orientation th
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
2. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
3. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
4. Japanese Cancer Association and Debiopharm Honour Japanese Research
5. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
6. Debiopharm and EPFL Establish an Oncology Chair
7. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
8. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
9. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
10. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
11. PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... State of Qatar to Introduce State-of-the-Art Treatments including ... the leading cancer centers in the Middle East ... Medical Systems (NYSE: VAR ) equipped ... Al Amal Hospital in Doha, Qatar, is replacing ...
... EU, LATAM and AfricaSAINT JOHN, New Brunswick, March 11 ... of ThyroChek, the rapid test for elevated TSH, the ... European Union. Until now, it has only been offered ... adults to the 200,000 physician office labs. With the ...
... Conference Call on Wednesday, March 11, 2009 at 4:30 ... - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... and fiscal year 2008 financial results, reviewed the Company,s ... was a tremendously active year from an execution standpoint ...
Cached Biology Technology:Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 2Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 3SD Canada Announces CE Mark for ThyroChek(R) Adult and NeoNatal Tests 2OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 2OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 3OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 4OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 5OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 6OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 7OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 8OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 9OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 10OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 11OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 12
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced today ... to confirm its adherence to current U.S. Food and ... conduct regulated smart device and smart phone application trials ... quality. "HITLAB is determined to improve global ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... gas seeping from the melting Arctic ice cap told Jeff ... permafrost thaws, there is a release of methane, a powerful ... figuring out how much, said Chanton, the John W. Winchester ... team whose findings were published in the respected journal ...
... at Baylor College of Medicine and Texas Children,s ... intestine that produce a neurotransmitter that may play ... diseases such as Crohn,s disease. "We identified, ... dentium, that is capable of secreting large amounts ...
... Department has recognized the University of Calgary, Sport Injury ... and preventing sports injuries. The Sport Injury Prevention ... named one of the IOC,s four international sport injury ... held on June 18, from 6 7:30pm at ...
Cached Biology News:Study: Seeking Arctic methane has serious implications for Florida coastline 2Intestinal bacteria produce neurotransmitter, could play role in inflammation 2IOC recognizes University of Calgary Sports Injury Research Prevention Centre 2
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Leucine-rich repeat-containing G-protein coupled receptor 4...
WD-repeat protein 4...
Biology Products: